triptorelin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 66 Diseases   138 Trials   138 Trials   1390 News 


12345678910111213...2122»
  • ||||||||||  triptorelin / Generic mfg.
    Trial initiation date, Trial primary completion date:  Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation (clinicaltrials.gov) -  Nov 14, 2024   
    P=N/A,  N=150, Not yet recruiting, 
    This study with a long follow-up period further highlights the usefulness of healthcare utilization databases to integrate results obtained from clinical studies with those from everyday clinical practice. Initiation date: Aug 2024 --> Dec 2024 | Trial primary completion date: Sep 2025 --> Dec 2025
  • ||||||||||  triptorelin / Generic mfg.
    P3 data, Journal:  A Phase (Pubmed Central) -  Nov 13, 2024   
    P3
    Initiation date: Aug 2024 --> Dec 2024 | Trial primary completion date: Sep 2025 --> Dec 2025 The efficacy and safety profile of triptorelin 6-month PR in Chinese children with CPP was consistent with data previously reported in non-Chinese children with CPP, supporting this as a viable treatment option for Chinese children with CPP.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Metastases:  EORTC-1206: Androgen Deprivation Therapy in Advanced Salivary Gland Cancer (clinicaltrials.gov) -  Nov 5, 2024   
    P2,  N=149, Completed, 
    The efficacy and safety profile of triptorelin 6-month PR in Chinese children with CPP was consistent with data previously reported in non-Chinese children with CPP, supporting this as a viable treatment option for Chinese children with CPP. Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Feb 2024
  • ||||||||||  triptorelin / Generic mfg.
    P4 data, Journal:  PRIORITI: Phase 4 study of triptorelin or active surveillance in high-risk prostate cancer. (Pubmed Central) -  Nov 4, 2024   
    P4
    Our findings are promising but more studies are needed to confirm if starting triptorelin shortly after surgery can benefit this group of people who have had their prostate cancer treated by radical prostatectomy and have no signs that their cancer has spread to the lymph nodes. [Correction added on 31th July 2024, after first online publication: Plain language summary is added in this version.].
  • ||||||||||  triptorelin / Generic mfg.
    Journal:  Central Precocious Puberty in a Male Child With Down Syndrome: A Case Report. (Pubmed Central) -  Sep 30, 2024   
    Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026 At age 10, following a three-year course of gonadotropin-releasing hormone (GnRH) agonist therapy, the patient demonstrated a notable decrease in testicular size
  • ||||||||||  abiraterone acetate / Generic mfg., triptorelin / Generic mfg.
    An extremely rare association of large plaque parapsoriasis with advanced prostate adenocarcinoma (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_3318;    
    To the best of our knowledge, this is the first report of LPP in the context of prostate adenocarcinoma, maybe an underdiagnosed association due to the asymptomatic course of disease and the need for expert training to raise clinical suspicion. It is essential to differentiate LPP from MF by performing multiple skin biopsies on suspicious lesions and to perform follow-up every three to six months for evidence of progression.
  • ||||||||||  Erleada (apalutamide) / J&J
    Lichenoid Drug Eruption Induced by Apalutamide (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_1959;    
    Lichenoid drug eruption is a rare adverse event associated with apalutamide therapy in patients with metastatic prostate carcinoma. The clinical and histological characteristics presented are useful for better understanding the associated mechanisms in future studies, contributing to the approach to this adverse event, improving patients
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov) -  Jul 22, 2024   
    P2,  N=32, Active, not recruiting, 
    These herbal compounds may have the potential therapeutic effect to be used as an alternative medication for the treatment of endometriosis. Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jul 2028 | Trial primary completion date: Jan 2027 --> Jul 2027
  • ||||||||||  goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
    Journal, Adverse events:  A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases. (Pubmed Central) -  Jul 19, 2024   
    A second dose of GnRH agonist 12 hours after the first dose did not improve the number and maturity of oocytes, or pregnancy outcomes in PCOS patients (registration number: NCT04600986). Employing two algorithms, the suspicious preferred terms (PTs) related to leuprolide (Leu) were 562 potential PTs (44 unlisted in specifications), followed by goserelin (Gos) with 189
  • ||||||||||  triptorelin / Generic mfg.
    Journal:  Diagnostic value of stimulated urine luteinizing hormone after triptorelin stimulation test in girls with CPP. (Pubmed Central) -  Jul 16, 2024   
    The ULH detection method after the triptorelin stimulation test has clinical significance for diagnosing CPP in girls. When blood sampling compliance in girls with precocious puberty is poor, the first 12-hour ULH/Cr?288 IU/mol (or second 12-hour?153 IU/mol) after the triptorelin stimulation test can serve as a laboratory indicator for diagnosis of CPP.